Viatris Inc (VTRS) KPIs and segments
Close on Nov 18, 2026Market cap $23.29BP/E –Yield 2.37%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Viatris · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Viatris: 51 chỉ số vận hành, trong đó có New Product Launches Net Sales, Developed Markets — North America Net Sales và Developed Markets — Europe Net Sales, lấy từ 139 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Developed Markets Segment($M)2 | 2,203 | 2,026 | 2,258 | 2,266 | 2,130 | 1,899 | 2,156 | 2,308 | 2,325 | 2,173 | 2,345 | ||
Brands($M) | 1,122 | 1,069 | 1,189 | 1,241 | 1,121 | 1,020 | 1,101 | 1,218 | 1,234 | 1,179 | 1,316 | ||
Generics($M) | 1,071 | 952 | 1,059 | 1,014 | 998 | 872 | 1,045 | 1,081 | 1,085 | 987 | 1,004 | ||
Greater China($M)2 | 714 | 680 | 573 | 615 | 589 | 556 | 522 | 562 | 539 | 544 | 515 | ||
Brands($M) | 711 | 677 | 570 | 612 | 587 | 553 | 520 | 559 | 536 | 542 | 513 | ||
Generics($M) | 3 | 2.90 | 2.70 | 2.90 | 2.40 | 2.70 | 2 | 2.40 | 3.30 | 2.10 | 2.60 | ||
Emerging Markets Segment($M)2 | 544 | 537 | 566 | 572 | 557 | 523 | 514 | 535 | 582 | 629 | 630 | ||
Brands($M) | 441 | 447 | 431 | 424 | 416 | 403 | 372 | 396 | 395 | 404 | 375 | ||
Generics($M) | 101 | 88.2 | 134 | 146 | 139 | 117 | 141 | 137 | 183 | 222 | 244 | ||
Japan, Australia and New Zealand Segment($M)2 | 296 | 274 | 307 | 307 | 307 | 277 | 336 | 346 | 350 | 318 | 373 | ||
Generics($M) | 152 | 134 | 150 | 147 | 145 | 134 | 162 | 155 | 151 | 134 | 173 | ||
Brands($M) | 144 | 139 | 156 | 159 | 161 | 142 | 172 | 189 | 198 | 184 | 200 | ||
Brands($M) | 2,418 | 2,333 | 2,346 | 2,437 | 2,285 | 2,117 | 2,166 | 2,362 | 2,363 | 2,309 | 2,402 | ||
Generics($M) | 1,328 | 1,177 | 1,345 | 1,311 | 1,285 | 1,126 | 1,350 | 1,376 | 1,423 | 1,344 | 1,424 | ||
Lipitor($M) | 452 | 462 | 377 | 396 | 388 | 388 | 356 | 376 | 348 | 389 | 380 | ||
Norvasc($M) | 200 | 210 | 175 | 180 | 183 | 172 | 166 | 169 | 162 | 176 | 172 | ||
EpiPen Auto-Injectors($M) | 129 | 101 | 79 | 157 | 137 | 96.7 | 73.1 | 123 | 116 | 80.2 | 87 | ||
Lyrica($M) | 121 | 121 | 120 | 127 | 128 | 113 | 127 | 130 | 124 | 114 | 133 | ||
Viagra($M) | 113 | 95 | 104 | 105 | 100 | 98.5 | 88.6 | 100 | 106 | 101 | 92.3 | ||
Creon($M) | 97.4 | 97.4 | 98.9 | 93.1 | 91.4 | 82.4 | 90.4 | 84.6 | 78.2 | 75 | 80.6 | ||
Celebrex($M) | 76.4 | 67.1 | 66.2 | 73.3 | 70 | 63.4 | 67.1 | 74.1 | 72.2 | 72.2 | 75.1 | ||
Zoloft($M) | 71.4 | 72.6 | 66.8 | 66.8 | 61.1 | 60.2 | 58.2 | 60.6 | 58.9 | 58 | 62 | ||
Yupelri($M) | 70.7 | 62.5 | 70.6 | 71.4 | 66.6 | 58.3 | 66.6 | 62.2 | 54.5 | 55.2 | 60.5 | ||
Effexor($M) | 66.7 | 62 | 68.1 | 67.2 | 63.1 | 59.3 | 64.5 | 66.3 | 62.7 | 59.4 | 68 | ||
Influvac($M) | 63.6 | 125 | 52.7 | 121 | 54.9 | ||||||||
Dymista($M) | 39.8 | 37.3 | 38.6 | 33.8 | 48.4 | 42.8 | 41.3 | 43.5 | 55 | 48.2 | 45 | ||
Amitiza($M) | 39.4 | 34 | 42.4 | 40.8 | 41.6 | 33.3 | 41.1 | 38.2 | 36.9 | 33 | 41.2 | ||
Xalabrands($M) | 38.8 | 39.2 | 42 | 38.6 | 40.7 | 37.1 | 37.1 | 41.2 | 45.6 | 42.5 | 48.2 | ||
Xanax($M) | 38.1 | 34.8 | 39.5 | 34.2 | 33.9 | 32.3 | 36.5 | 38.6 | 35.4 | 34.5 | 35.1 | ||
Developed Markets Segment($M) | 937 | 781 | 944 | 876 | 738 | 1,042 | 1,008 | 913 | 1,001 | ||||
Greater China($M) | 510 | 497 | 417 | 402 | 385 | 362 | 349 | 366 | 328 | ||||
Emerging Markets Segment($M) | 232 | 247 | 234 | 238 | 236 | 208 | 233 | 280 | 228 | ||||
Japan, Australia and New Zealand Segment($M) | 76.3 | 64.7 | 70.2 | 83.7 | 62.2 | 103 | 101 | 87.3 | 135 | ||||
New Product Launches Net Sales($M) | 115 | 101 | 70.7 | 78 | 99.5 | 79.4 | 66.8 | 85 | 133 | 210 | 154 | ||
Developed Markets — North America Net Sales($M) | 923 | 883 | 828 | 850 | 868 | 870 | 801 | 910 | 991 | 986 | 898 | 950 | |
Developed Markets — Europe Net Sales($M) | 1,290 | 1,310 | 1,190 | 1,390 | 1,390 | 1,250 | 1,090 | 1,240 | 1,310 | 1,330 | 1,270 | 1,370 | |
Top 10 Products Concentration (% of Net Sales)(%) | 41.0% | 38.0% | 40.0% | 38.0% | 37.0% | 38.0% | 36.0% | 33.0% | 34.0% | ||||
Operational (Constant-Currency) Net Sales Growth YoY(%)7 | 0.0% | 4.0% | 3.0% | 1.0% | -2.0% | -7.0% | -9.0% | -7.0% | -5.0% | -1.0% | 0.0% | -2.0% | |
Total Revenues — Operational Growth YoY(%) | 0.0% | 4.0% | 3.0% | 1.0% | -2.0% | -7.0% | -9.0% | -7.0% | -4.0% | -1.0% | 0.0% | -2.0% | |
Developed Markets — Operational Net Sales Growth YoY(%) | -1.0% | 2.0% | 1.0% | 0.0% | -5.0% | -11.0% | -11.0% | -7.0% | -5.0% | -1.0% | -1.0% | -5.0% | |
Greater China — Operational Net Sales Growth YoY(%) | 10.0% | 16.0% | 18.0% | 8.0% | 9.0% | 9.0% | 4.0% | 2.0% | 3.0% | 5.0% | 0.0% | 2.0% | |
JANZ — Operational Net Sales Growth YoY(%) | -5.0% | 0.0% | -2.0% | -8.0% | -10.0% | -14.0% | -9.0% | -7.0% | 6.0% | 1.0% | 2.0% | -2.0% | |
Emerging Markets — Operational Net Sales Growth YoY(%) | -6.0% | -2.0% | 0.0% | 8.0% | 7.0% | -3.0% | -13.0% | -13.0% | -14.0% | -6.0% | 4.0% | 10.0% | |
Brands Portfolio — Operational Net Sales Growth YoY(%) | 1.0% | 4.0% | 4.0% | 4.0% | 1.0% | -5.0% | -5.0% | -8.0% | -6.0% | 0.0% | -2.0% | ||
Generics Portfolio — Operational Net Sales Growth YoY(%) | -3.0% | 3.0% | 1.0% | -3.0% | -6.0% | -11.0% | -15.0% | -5.0% | -2.0% | -2.0% | 5.0% | ||
Foreign Currency Translation Impact on Total Revenues($M)5 | 2.20 | -49.3 | -162 | -125 | -76.7 | -61.8 | 85.2 | 48.9 | 14.5 | 98.9 | 77.2 | -23.5 | |
Total Gross-to-Net Sales Deductions & Allowances($M)4 | 2,125 | 2,333 | 2,414 | 2,289 | 2,461 | 2,406 | 2,327 | 2,495 | 2,598 | 2,598 | 2,521 | 2,578 | |
Wholesaler Chargebacks($M) | 1,044 | 1,162 | 1,178 | 1,132 | 1,266 | 1,261 | 1,158 | 1,198 | 1,284 | 1,283 | 1,244 | 1,385 | |
Commercial Rebates, Promotional & Other Allowances($M) | 879 | 971 | 1,049 | 941 | 975 | 918 | 971 | 1,062 | 1,043 | 1,041 | 1,048 | 952 | |
Medicaid & Governmental Rebate Programs($M) | 153 | 157 | 145 | 140 | 171 | 179 | 144 | 164 | 181 | 205 | 168 | 193 | |
Product Sales Returns Provision($M) | 49.4 | 43.4 | 43.5 | 75.8 | 48.7 | 47.8 | 54.3 | 71.8 | 90.3 | 70.1 | 60.3 | 48.8 | |
Gross Product Sales (Before Rebates & Chargebacks)($M)2 | 5,860 | 6,079 | 5,924 | 5,980 | 6,208 | 5,975 | 5,570 | 6,011 | 6,336 | 6,384 | 6,175 | 6,404 | |
Consolidated Net Product Sales (After GTN Deductions)($M) | 3,735 | 3,746 | 3,510 | 3,691 | 3,748 | 3,569 | 3,243 | 3,515 | 3,738 | 3,786 | 3,654 | 3,826 | |
Other Revenues (Contract Manufacturing, Royalties & TSA)($M) | 14.8 | 10.9 | 7.30 | 12.9 | 12.4 | 13.1 | 11.1 | 12.7 | 13.2 | 10.7 | 9.90 | 11.4 | |
Gross-to-Net Sales Allowance Reserves (Ending Balance)($M)2 | 2,096 | 2,106 | 2,200 | 2,269 | 2,493 | 2,464 | 2,517 | 2,536 | 2,596 | 2,547 | 2,491 | 2,480 | |
Contra-Accounts Receivable Sales Allowances($M) | 1,154 | 1,207 | 1,223 | 1,257 | 1,409 | 1,418 | 1,503 | 1,547 | 1,565 | 1,553 | 1,483 | 1,484 | |
Accrued Sales Allowances (Other Current Liabilities)($M) | 942 | 900 | 978 | 1,011 | 1,083 | 1,046 | 1,014 | 989 | 996 | ||||
Accounts Receivable Securitization & Factoring Proceeds($M) | -101 | -45.2 | 296 | 0 | 0 | 210 | 92.2 | 0 | 0 | 37.7 | 30.8 | 9.50 | |
Pipeline & BD Contingent Consideration Liability (Level 3 Fair Value)($M)6 | 441 | 464 | 449 | 372 | 382 | 367 | 412 | 556 | 541 | 515 | 570 | 215 | |
Idorsia R&D Collaboration Liability (Selatogrel & Cenerimod Phase 3)($M) | 411 | 421 | 392 | 307 | 300 | 288 | 270 | 378 | 389 | 345 | 345 | ||
Respiratory Delivery Platform Contingent Liability($M) | 29.8 | 42.6 | 57.2 | 64.6 | 79.8 | 77.5 | 141 | 176 | 150 | 160 | 173 | 178 | |
Contingent Consideration — Current Portion($M) | 18.5 | 18.9 | 27.7 | 28.5 | 36.9 | 37.1 | 44.7 | 59.5 | 49.8 | 76.1 | |||
Contingent Consideration — Noncurrent Portion($M) | 422 | 445 | 421 | 343 | 345 | 330 | 368 | 497 | 491 | 139 | |||
Contingent Consideration Fair Value Remeasurement (Gain) / Loss($M) | -17.5 | 21.2 | 84.5 | -1.10 | 21.1 | -37.7 | -134 | 26.4 | 26.8 | -3.20 | 4.80 | 67.8 | |
Contingent Consideration Cash Settlements Paid($M) | 6.10 | 7.60 | 7.90 | 9.90 | 7.80 | 8.50 | 11.4 | 12.2 | 12.2 | 61.7 | 10.9 | 229 | |
Finished Goods Inventory (Net of Reserves)($M)3 | 1,964 | 2,001 | 2,032 | 2,085 | 2,085 | 2,185 | 2,163 | 1,981 | 2,244 | 2,119 | 2,039 | 2,136 | |
Raw Materials & Supplies Inventory($M) | 1,393 | 1,458 | 1,470 | 1,422 | 1,511 | 1,547 | 1,439 | 1,346 | 1,286 | 1,246 | 687 | 732 | |
Work in Process (WIP) Inventory($M) | 473 | 475 | 425 | 492 | 516 | 532 | 494 | 527 | 555 | 577 | 1,098 | 602 | |
Total Inventories (Footnote Disaggregation Check)($M) | 3,829 | 3,933 | 3,927 | 3,999 | 4,111 | 4,264 | 4,096 | 3,854 | 4,085 | 3,942 | 3,823 | 3,470 | |
PP&E Gross — Machinery & Manufacturing Equipment($M)5 | 3,175 | 3,056 | 3,039 | 3,043 | 3,045 | 3,040 | 2,950 | 2,895 | 2,862 | 2,752 | 2,746 | 2,775 | |
Operating Lease Right-of-Use (ROU) Assets($M)2 | 251 | 259 | 253 | 271 | 266 | 276 | 266 | 253 | 268 | 273 | 242 | 246 | |
Segment Adjusted Cost of Sales — Developed Markets($M)3 | 998 | 1,036 | 1,012 | 1,067 | 1,093 | 1,005 | 926 | 995 | 1,018 | 1,025 | 976 | ||
Segment Adjusted Cost of Sales — Emerging Markets($M) | 240 | 237 | 220 | 249 | 265 | 240 | 213 | 231 | 249 | 272 | 265 | ||
Segment Adjusted Cost of Sales — JANZ($M) | 181 | 180 | 174 | 177 | 199 | 182 | 177 | 199 | 203 | 207 | 189 | ||
Segment Adjusted Cost of Sales — Greater China($M) | 79.4 | 77.4 | 70.9 | 61.9 | 65.4 | 62.5 | 60.8 | 60 | 65.3 | 59.2 | 61.2 | ||
Segment Adjusted SG&A Expense — Developed Markets($M)3 | 226 | 230 | 233 | 255 | 229 | 250 | 234 | 274 | 248 | 292 | 283 | ||
Segment Adjusted SG&A Expense — Emerging Markets($M) | 68.9 | 74.4 | 71.1 | 83.7 | 73.6 | 78.4 | 74.3 | 69.8 | 78.1 | 78 | 84 | ||
Segment Adjusted SG&A Expense — Greater China($M) | 139 | 127 | 112 | 145 | 133 | 125 | 110 | 137 | 135 | 131 | 116 | ||
Segment Adjusted SG&A Expense — JANZ($M) | 42.1 | 39.6 | 34.4 | 41.3 | 37.9 | 41.3 | 38.4 | 45.6 | 40.1 | 41.2 | 41.4 | ||
Segment Goodwill Carrying Value — Developed Markets($M)3 | 4,881 | 4,918 | 4,962 | 5,025 | 5,005 | 5,019 | 4,742 | 6,753 | 7,143 | 6,946 | 6,973 | 7,107 | |
Adjusted EBITDA (Non-GAAP)($M)3 | 1,196 | 1,188 | 1,050 | 1,003 | 1,155 | 1,079 | 924 | 984 | 1,285 | 1,208 | 1,193 | 1,117 | |
Adjusted EBITDA — Operational Growth YoY(%) | 1.0% | 8.0% | 10.0% | -1.0% | -10.0% | -12.0% | -20.0% | -12.0% | -5.0% | -5.0% | -9.0% | ||
EBITDA (Unadjusted)($M) | 938 | 729 | 549 | 543 | 800 | 578 | -2,317 | 340 | 906 | 540 | 1,034 | -69.7 | |
EBITDA Adjustment — Restructuring, M&A & Special Items($M) | 230 | 347 | 385 | 264 | 468 | 285 | 208 | -77.9 | 106 | ||||
Adjusted Gross Profit (Non-GAAP)($M)4 | 2,176 | 2,159 | 1,970 | 2,103 | 2,104 | 2,028 | 1,820 | 1,987 | 2,193 | 2,204 | 2,155 | 2,208 | |
Adjusted Gross Margin(%) | 58.0% | 57.5% | 56.0% | 56.8% | 56.0% | 56.6% | 55.9% | 56.3% | 58.5% | 58.0% | 58.8% | ||
U.S. GAAP Gross Margin(%) | 38.4% | 38.8% | 32.9% | 31.0% | 36.5% | 37.2% | 35.7% | 34.4% | 38.9% | 38.1% | 41.1% | ||
Adjusted Cost of Sales($M) | 1,574 | 1,598 | 1,547 | 1,600 | 1,656 | 1,554 | 1,435 | 1,541 | 1,629 | ||||
Purchase Accounting Intangible Amortization($M) | 614 | 586 | 592 | 683 | 606 | 598 | 584 | 674 | 586 | 710 | 612 | ||
Adjusted Earnings from Operations (Non-GAAP)($M)9 | 1,120 | 1,102 | 949 | 909 | 1,046 | 991 | 813 | 871 | 987 | ||||
Adjusted Net Earnings (Non-GAAP)($M)4 | 821 | 809 | 694 | 659 | 784 | 726 | 600 | 656 | 898 | 827 | 813 | ||
Adjusted Diluted EPS($) | 0.71 | 0.69 | 0.59 | 0.57 | 0.67 | 0.62 | 0.50 | 0.54 | 0.75 | 0.69 | 0.67 | ||
Adjusted Diluted EPS — Operational Growth YoY(%) | 3.0% | 9.0% | 14.0% | 0.0% | -10.0% | -12.0% | -23.0% | -12.0% | -5.0% | -5.0% | -11.0% | ||
Adjusted Weighted-Average Diluted Shares(M) | 1,161 | 1,172 | 1,175 | 1,166 | 1,172 | 1,177 | 1,203 | 1,203 | 1,200 | 1,198 | 1,210 | ||
Acquisition & Divestiture-Related Pre-Tax Costs($M) | 44.5 | 51.4 | 62.3 | 73.8 | 40 | 53.7 | 40.7 | 70 | 98.2 | 105 | 87.5 | 148 | |
Free Cash Flow (Operating Cash Flow Less CapEx)($M)2 | 814 | 329 | 348 | 619 | 658 | 167 | 493 | 342 | 750 | 320 | 565 | ||
Free Cash Flow Excluding Transaction & Restructuring Costs($M) | 728 | 241 | 459 | 685 | 866 | 426 | |||||||
Transaction-Related & Restructuring Cash Costs Impacting FCF($M) | 70 | 74 | 111 | 343 | 116 | 106 | |||||||
Finite-Lived Intangible Assets, Net (Acquired Product Rights & Licenses)($M)8 | 12,405 | 12,971 | 13,776 | 14,396 | 14,945 | 15,522 | 15,858 | 16,257 | 17,087 | 17,527 | 18,140 | 18,862 | |
Finite-Lived Intangible Assets — Gross Carrying Amount($M) | 33,725 | 33,820 | 34,316 | 34,507 | 34,810 | 34,906 | 33,905 | 33,349 | 34,275 | 33,753 | 33,830 | 34,178 | |
Finite-Lived Intangible Assets — Accumulated Amortization($M) | 21,321 | 20,849 | 20,539 | 20,111 | 19,865 | 19,384 | 18,047 | 17,092 | 17,188 | 16,226 | 15,691 | 15,316 | |
Indefinite-Lived In-Process R&D (IPR&D) Intangible Assets($M) | 675 | 706 | 706 | 706 | 778 | 802 | 804 | 814 | 892 | 892 | 994 | 319 | |
Intangible Assets Amortization Expense($M) | 558 | 572 | 585 | 602 | 593 | 583 | 571 | 579 | 575 | 597 | 601 | 539 | |
Estimated Intangible Amortization — Year +1 (Next 12 Months)($M) | 2,023 | 2,034 | 2,069 | 2,337 | 2,329 | 2,324 | 2,251 | 2,228 | 2,296 | 2,261 | 2,255 | 2,314 | |
Estimated Intangible Amortization — Year +2($M) | 1,770 | 1,779 | 1,811 | 2,115 | 2,107 | 2,103 | 2,034 | 2,179 | 2,243 | 2,213 | 2,205 | 2,235 | |
Estimated Intangible Amortization — Year +3($M) | 1,190 | 1,190 | 1,213 | 1,853 | 1,846 | 1,840 | 1,793 | 1,966 | 2,025 | 1,993 | 2,006 | 2,183 | |
Estimated Intangible Amortization — Year +4($M) | 1,183 | 1,184 | 1,206 | 1,243 | 1,240 | 1,235 | 1,233 | 1,738 | 1,781 | 1,758 | 1,769 | 2,102 | |
Global Restructuring Accrual Reserve (2020 & 2026 Programs)($M)7 | 87 | 60.8 | 69.8 | 0 | |||||||||
Restructuring Reserve — Current($M) | 57 | 52.2 | 59.2 | 40.2 | 34 | 44.7 | 134 | 63.4 | 30.9 | 29.4 | 29.9 | 36.4 | |
Restructuring Reserve — Noncurrent($M) | 163 | 152 | 155 | 116 | 130 | 130 | 131 | 129 | 128 | 60.9 | 57.9 | 59.2 | |
Restructuring Reserve — Employee Severance & Benefits($M) | 87 | 60.8 | 69.8 | 0 | |||||||||
Restructuring Reserve — Site Exit & Other Costs($M) | 0 | 0 | 0 | 0 | |||||||||
Restructuring Charges — Employee Severance($M) | 47.2 | 22.9 | 75.8 | ||||||||||
Restructuring Charges — Other Exit Costs($M) | 4.90 | 4.40 | 2.10 | ||||||||||
Restructuring Cash Payments Settled($M) | 20.3 | 31.4 | 5.90 | ||||||||||
Litigation & Legal Contingency Accrual — Current Portion($M)5 | 309 | 303 | 294 | 326 | 556 | 541 | 526 | 473 | 446 | 453 | 322 | 244 | |
Nationwide Opioid Civil Settlement Accrual (Total Carrying Value)($M) | 281 | 281 | 281 | 335 | 335 | 335 | 335 | 270 | 270 | 270 | 151 | 77.5 | |
Product Liability Contingency Accrual($M) | 35.6 | 35.7 | 35.5 | 67.1 | 67.3 | 66.8 | 66.8 | 70.1 | 65.9 | 65.7 | 65.3 | 64.9 | |
Other Legal Contingencies Accrual($M) | 17 | 9 | 7 | 9.10 | 9 | 8 | 7 | 5.70 | 8 | 20 | 6.50 | 6.60 | |
Generic Drug Pricing Litigation — Participating U.S. States & Territories (AG Complaint) | 44 | 44 | 44 | 44 | 44 | 44 | 45 | 45 | 44 | 45 | 45 | 45 | |
Generic Drug Multidistrict Litigation (MDL) — Plaintiff States | 42 | 42 | 42 | 42 | 42 | 42 | 43 | 43 | 43 | 44 | 44 | 44 | |
Gain / (Loss) on Divestitures of Businesses($M) | 0 | 0 | -13.9 | -21.9 | 1.60 | -43.8 | -36.9 | -104 | -107 | -259 | 70.4 | -240 | |
Senior Notes Carrying Portfolio — Fair Value($M) | 10,690 | 11,110 | 11,810 | 11,990 | 11,980 | 11,810 | 11,410 | 11,530 | 13,400 | 14,220 | 15,090 | 15,250 | |
Nonvested Restricted Stock Units (RSUs & PRSUs Outstanding)(M)4 | 29.1 | 29.7 | 31.2 | 32.9 | 33.4 | 33.8 | 34.3 | 29.1 | 29.5 | 30.6 | 32.8 | 31.1 | |
Defined Benefit Pension & Postretirement Noncurrent Liability($M)4 | 399 | 414 | 433 | 426 | 479 | 488 | 474 | 468 | 491 | 488 | 495 | 504 | |
Deferred Income Tax Assets, Net($M)2 | 1,173 | 1,158 | 1,109 | 1,061 | 999 | 924 | 818 | 753 | 763 | 685 | 653 | 693 | |
Pacira BioSciences, Inc. (PCRX) — Total Revenues($M)6 | 177 | 192 | 177 | 197 | 180 | 181 | 169 | 187 | 169 | 178 | 167 | 181 | |
Pacira BioSciences, Inc. (PCRX) — Total Net Product Sales($M)4 | 175 | 191 | 177 | 197 | 178 | 180 | 168 | 187 | 168 | 176 | 166 | 180 | |
Pacira BioSciences, Inc. (PCRX) — EXPAREL Net Product Sales($M) | 143 | 148 | 143 | 156 | 140 | 143 | 137 | 148 | 132 | 137 | 132 | 144 | |
Pacira BioSciences, Inc. (PCRX) — ZILRETTA Net Product Sales($M) | 29.8 | 32.6 | 26.8 | 33 | 29 | 31.3 | 23.3 | 33.1 | 28.4 | 30.7 | 25.8 | 28.7 | |
Pacira BioSciences, Inc. (PCRX) — iovera° Net Product Sales($M) | 2 | 6.80 | 6.20 | 7 | 6.50 | 5.60 | 5.10 | 6.50 | 5.70 | 5.70 | 5 | 6 | |
Pacira BioSciences, Inc. (PCRX) — Bupivacaine Liposome Veterinary Sales($M) | 1.20 | 3.20 | 1.20 | 1.10 | 2.70 | 0.50 | 2.60 | 0 | 1.60 | 3.20 | 2.50 | 1.10 | |
Pacira BioSciences, Inc. (PCRX) — Royalty & Collaborative Revenue($M) | 0 | 1.90 | 0 | 0 | 1.50 | 0.80 | 1.30 | 0 | 0.90 | 1.60 | 1.30 | 1.50 | |
Pacira BioSciences, Inc. (PCRX) — GAAP Operating Income($M) | 22.3 | 4.30 | 6.90 | 2.30 | 6.40 | 8.50 | 2 | 24.7 | -140 | 28.2 | 13.2 | 33.2 | |
Pacira BioSciences, Inc. (PCRX) — Research & Development Expense($M) | 26.7 | 30.2 | 28.1 | 37.5 | 26 | 28.2 | 25.3 | 23.9 | 19.1 | 20.3 | 18.2 | 19.5 | |
Pacira BioSciences, Inc. (PCRX) — Selling, General & Administrative Expense($M) | 83.8 | 91.8 | 93.9 | 102 | 91.8 | 88.6 | 86.8 | 79.6 | 74.3 | 68.1 | 72 | 65.8 | |
Pacira BioSciences, Inc. (PCRX) — GAAP Net Income($M) | 28.5 | 4.70 | 2.90 | 1.60 | 5.40 | -4.80 | 4.80 | 16 | -144 | 18.9 | 9 | 24.9 | |
U.S. Personal Consumption Expenditures — Health Care (SAAR)($M) | 3,858,670 | 3,790,290 | 3,699,900 | 3,666,990 | 3,614,850 | 3,529,830 | 3,464,650 | 3,417,830 | 3,358,240 | 3,288,220 | 3,244,360 | 3,159,380 | |
Total Revenues($M)13 | 3,750 | 3,757 | 3,517 | 3,704 | 3,760 | 3,582 | 3,254 | 3,528 | 3,751 | 3,797 | 3,663 | 3,837 | |
Cost of Sales($M) | 2,312 | 2,300 | 2,360 | 2,556 | 2,388 | 2,249 | 2,093 | 2,313 | 2,292 | 2,351 | 2,159 | 2,241 | |
Gross Profit($M) | 1,438 | 1,457 | 1,157 | 1,148 | 1,372 | 1,333 | 1,161 | 1,215 | 1,459 | 1,445 | 1,504 | 1,597 | |
Research & Development Expense($M) | 232 | 248 | 249 | 275 | 250 | 219 | 222 | 207 | 198 | 204 | 200 | 203 | |
Selling, General & Administrative Expense($M) | 951 | 1,135 | 929 | 1,031 | 887 | 929 | 948 | 1,047 | 1,003 | 1,037 | 1,018 | 1,026 | |
Litigation Settlements & Other Contingencies, Net($M) | 11 | -73.2 | -53.5 | 3.10 | -55.7 | 47.6 | 73.5 | -112 | -31.5 | -131 | -76.8 | -148 | |
Earnings (Loss) from Operations($M) | 262 | 6.30 | -79.7 | -193 | 179 | 233 | -2,882 | -180 | 226 | -240 | 204 | -455 | |
Interest Expense($M) | 112 | 121 | 120 | 120 | 120 | 117 | 116 | 120 | 146 | 146 | 138 | 141 | |
Earnings (Loss) Before Income Taxes($M) | 128 | -64 | -247 | -343 | -7.90 | -217 | -3,097 | -527 | 90.5 | -392 | 205 | -855 | |
Income Tax Provision (Benefit)($M) | 453 | 54.8 | -424 | -2.90 | 120 | -213 | -55 | -10 | -4.30 | -65.4 | 90.7 | -89.4 | |
Net Earnings (Loss) Attributable to Common Shareholders($M) | -325 | -119 | 176 | -128 | -4.60 | -3,042 | 94.8 | -326 | 114 | ||||
Diluted Earnings (Loss) Per Share($) | -0.28 | -0.10 | 0.15 | -0.11 | 0 | -2.55 | 0.08 | -0.27 | 0.09 | ||||
Weighted-Average Diluted Shares Outstanding(M) | 1,149 | 1,163 | 1,175 | 1,165 | 1,173 | 1,192 | 1,200 | 1,191 | 1,210 | ||||
Dividends Per Share($) | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | |
Total Assets($M)12 | 34,683 | 35,045 | 36,835 | 37,193 | 37,920 | 38,412 | 38,475 | 41,501 | 44,754 | 45,330 | 47,344 | 47,686 | |
Operating Cash Flow($M)6 | 899 | 382 | 388 | 816 | 745 | 220 | 536 | 483 | 827 | 379 | 615 | 569 | |
6 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar: Viatris Inc. (formed November 16, 2020 through the combination of Mylan N.V. and Pfizer's Upjohn business) operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026). Pre-combination periods prior to Q4 2020 reflect Mylan N.V. historical accounting basis.
- Commercial, Pricing & Pipeline KPIs: Standard segment and legacy brand revenue tables already displayed in the platform's segment header are not duplicated here. Instead, this sheet tracks New Product Launches Net Sales ($115.2M in Q3 2026; $323.7M in FY2025), Top-10 Product Concentration (41% in Q3 2026), North America ($923.4M) vs. Europe ($1,290.0M) net sales within Developed Markets, constant-currency operational growth & FX bridges, the full Gross-to-Net (GTN) variable consideration waterfall ($5,860.1M gross sales less $2,125.4M GTN deductions = $3,734.7M net sales in Q3 2026; $9,482.5M GTN deductions in FY2025), GTN reserves ($2,096.3M at Q3 2026), wholesaler concentration, Board-audited Global Regulatory Submissions (110 in FY2025), active development programs & customer service levels by segment, WHO prequalified essential medicines (49 in FY2025), and Idorsia Phase 3 contingent consideration ($411.0M at Q3 2026).
- Pending Acquisition & Industry Context: On October 8, 2026, Viatris announced a definitive agreement to acquire Pacira BioSciences, Inc. (Nasdaq: PCRX) for $36.50 per share in cash ($1.65B equity value), expected to close by the end of November 2026. Standalone historical SEC XBRL product sales of Pacira (EXPAREL $142.5M, ZILRETTA $29.8M, iovera $2.0M in Q3 2026) are presented in the External section alongside monthly U.S. pharmaceutical PPI, CPI, and pharmacy retail sales series from FRED.
- Methodology: No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated minus Standalone subtraction is performed. All figures are strictly as published (with verbatim hover quotes for text-extracted values; bound disclosures such as '>70B doses' are excluded). The only arithmetic used in derived cells is period splitting (Q4 = full year minus nine months; quarter = year-to-date minus prior year-to-date), shown in italic with the formula.
Không hiện vì thiếu các kỳ gần đây (13)
- Gross-to-Net Pricing Waterfall, Rebates & Channel Concentration (Key #3) › Top 3 Wholesaler Customers Concentration (% of Accounts Receivable) › McKesson Corporation Share of Consolidated Net Sales (Legacy ≥10% Threshold) — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
- Gross-to-Net Pricing Waterfall, Rebates & Channel Concentration (Key #3) › Top 3 Wholesaler Customers Concentration (% of Accounts Receivable) › Cardinal Health Share of Consolidated Net Sales (Legacy Disclosure) — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
- Global Pipeline, Regulatory Submissions & Collaboration Liabilities (Key #4) › Products in Active Development — Developed Markets › Products Pending Regulatory Approval — Developed Markets — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
- Global Pipeline, Regulatory Submissions & Collaboration Liabilities (Key #4) › Products in Active Development — Developed Markets › Products Pending Regulatory Approval — Emerging Markets — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
- Global Pipeline, Regulatory Submissions & Collaboration Liabilities (Key #4) › WHO Prequalified Essential Medicines Portfolio (Total) › Active & Pending Patents Maintained Globally — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
- Intangible Amortization Schedule, Restructuring, Litigation & Divestitures › Gain / (Loss) on Divestitures of Businesses › Biocon Biologics / Biocon Equity Fair Value Gain / (Loss) — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
- Debt Maturity Schedule, Leverage, Equity Awards, Pensions & Taxes › Senior Notes Carrying Portfolio — Fair Value › Total Debt at Notional Principal Amounts — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
- Debt Maturity Schedule, Leverage, Equity Awards, Pensions & Taxes › Senior Notes Carrying Portfolio — Fair Value › Gross Leverage Ratio (Notional Debt / LTM Adjusted EBITDA) — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
- Debt Maturity Schedule, Leverage, Equity Awards, Pensions & Taxes › Senior Notes Carrying Portfolio — Fair Value › Trailing Twelve Months (LTM) Adjusted EBITDA — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
- Consolidated Financial Statements (U.S. GAAP Context) › Operating Cash Flow › Debt Repayments — Discontinued or lacks continuous recent periods (e.g., single-customer disclosure fell below 10% threshold after FY2023, or FY2025 sustainability table switched to a lower-bound '>' disclosure).
- Complex Generics & Biosimilars Product Category Revenue — Discontinued after Q3 2023 following the November 2022 divestiture of the biosimilars portfolio to Biocon Biologics and commercial category realignment.
- Annual Doses Sold & Countries Reached — Reported only as lower bounds ('>70 billion doses', '>80 billion doses', '>165 countries') in Viatris Sustainability Reports and Form 10-K.
- Global Health Authority Inspections Count — Reported only as a lower bound ('>95 health authority inspections' in FY2025) in Viatris Sustainability Reports.
Dữ liệu cập nhật 2026-11-16.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
New Product Launches & Developed Markets Regional Split (Key #1)
Constant-Currency Operational Growth & Portfolio Concentration (Key #2)
Gross-to-Net Pricing Waterfall, Rebates & Channel Concentration (Key #3)
- Total Gross-to-Net Sales Deductions & Allowances ($M)27 kỳ
- Gross Product Sales (Before Rebates & Chargebacks) ($M)27 kỳ
- Gross-to-Net Sales Allowance Reserves (Ending Balance) ($M)25 kỳ
- Accounts Receivable Securitization & Factoring Proceeds ($M)23 kỳ
- Top 3 Wholesaler Customers Concentration (% of Accounts Receivable) (%)6 kỳ
Global Pipeline, Regulatory Submissions & Collaboration Liabilities (Key #4)
Supply-Chain Service Levels, Manufacturing Footprint & Inventory Mix (Key #5)
Segment Significant Expenses (ASU 2023-07) & Non-GAAP Operating Metrics
- Segment Adjusted Cost of Sales — Developed Markets ($M)11 kỳ
- Segment Adjusted SG&A Expense — Developed Markets ($M)11 kỳ
- Segment Goodwill Carrying Value — Developed Markets ($M)26 kỳ
- Adjusted EBITDA (Non-GAAP) ($M)23 kỳ
- Adjusted Gross Profit (Non-GAAP) ($M)23 kỳ
- Adjusted Earnings from Operations (Non-GAAP) ($M)11 kỳ
- Adjusted Net Earnings (Non-GAAP) ($M)22 kỳ
- Free Cash Flow (Operating Cash Flow Less CapEx) ($M)22 kỳ
Intangible Amortization Schedule, Restructuring, Litigation & Divestitures
Debt Maturity Schedule, Leverage, Equity Awards, Pensions & Taxes
Global Workforce, Safety, Executive Governance & Environmental Footprint
- Total Global Workforce (Employees & Contingent Workers)6 kỳ
- CEO Pay Ratio (Multiple of Median Global Employee Compensation) (×)5 kỳ
- Total Recordable Incident Rate (TRIR per 200,000 Hours Worked)6 kỳ
- Scope 1 & 2 Greenhouse Gas Emissions (Market-Based, thousand metric tons CO2e)6 kỳ
- Total Energy Consumption (GWh)6 kỳ
- Total Water Withdrawal (thousand cubic meters)6 kỳ
- Total Operational Waste Generated (thousand metric tons)6 kỳ
Pending Acquisition (Pacira BioSciences) & Pharma Industry Macro (External)
- Pacira BioSciences, Inc. (PCRX) — Total Revenues ($M)31 kỳ
- U.S. Producer Price Index — Pharmaceutical Preparation Manufacturing (Jun 1981=100)106 kỳ
- U.S. Consumer Price Index — Medical Care Commodities (SA, 1982-84=100)105 kỳ
- U.S. Retail Sales — Pharmacies & Drug Stores (Seasonally Adjusted) ($M)104 kỳ
- U.S. Personal Consumption Expenditures — Health Care (SAAR) ($M)35 kỳ
Consolidated Financial Statements (U.S. GAAP Context)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Viatris
- SEC Form 10-Q (2026-11-05) ↗
- Viatris 2025 Sustainability Report ↗
- SEC Form 8-K Earnings Release (FY2026Q3) (0001792044-26-000053) ↗
- SEC Form 8-K Earnings Release (FY2025Q4) (0001792044-26-000010) ↗
- SEC Form 10-K (2026-02-26) ↗
- SEC Form 10-K (FY2025) (0001792044-26-000013) ↗
- SEC Form 10-Q (FY2026Q3) (0001792044-26-000057) ↗
- SEC Form 10-Q (2026-11-05) ↗
- SEC Form 10-K (2026-02-26) ↗
- SEC DEF 14A Proxy Statement (2026) (0001140361-26-013002) ↗
- Pacira BioSciences (PCRX) SEC 10-Q (2026-11-05) ↗
- Pacira BioSciences (PCRX) SEC 10-K (2026-02-26) ↗
See a number that looks wrong?